Harmony Biosciences appoints Jeffrey Dayno as permanent President & CEO; Aronin returns to non-executive Chairman

Harmony Biosciences Holdings, Inc.

Dr. Jeffrey Dayno appointed President and CEO effective April 24, 2023; also joins Board as Class I director.
Dayno previously served as Interim President and CEO since Jan 6, 2023, and CMO since 2017.
Jeffrey Aronin returns from Executive Chairman to non-executive Chairman of the Board.
Dayno's employment agreement: base salary $650,000, target bonus 75% of base (up to 100% under certain circumstances).
Dayno stated WAKIX could be a $1B+ narcolepsy franchise with additional $1B potential from other indications.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jeffrey M. Dayno

President and Chief Executive Officer

HRMY · Harmony Biosciences Holdings, Inc.

Effective: 2023-04-24
Filed: April 24, 2023, 7:59 PM ET

Dr. Jeffrey M. Dayno, the Company’s current Interim President and Chief Executive Officer and Chief Medical Officer, has been appointed by the Board of Directors of the Company (the “Board”) as President and Chief Executive Officer (“CEO”) of the Company.

Appointed

Jeffrey M. Dayno

Class I Director

HRMY · Harmony Biosciences Holdings, Inc.

Effective: 2023-04-24
Filed: April 24, 2023, 7:59 PM ET

Dr. Dayno has also been appointed to the Board as a Class I Director

Role change

Jeffrey S. Aronin

non-executive Chairman of the Board

HRMY · Harmony Biosciences Holdings, Inc.

Effective: 2023-04-24
Filed: April 24, 2023, 7:59 PM ET

Jeffrey S. Aronin, who has served at the Company’s Executive Chairman since January 2023, has returned to his prior role as non-executive Chairman of the Board, effective April 24, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey M. Dayno was appointed as President and Chief Executive Officer at Harmony Biosciences Holdings, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

Dr. Jeffrey M. Dayno, the Company’s current Interim President and Chief Executive Officer and Chief Medical Officer, has been appointed by the Board of Directors of the Company (the “Board”) as President and Chief Executive Officer (“CEO”) of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey M. Dayno was appointed as Class I Director at Harmony Biosciences Holdings, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

Dr. Dayno has also been appointed to the Board as a Class I Director

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey S. Aronin changed role as non-executive Chairman of the Board at Harmony Biosciences Holdings, Inc..

Action: returned to
Role: non-executive Chairman of the Board

Exact text from the filing

Jeffrey S. Aronin, who has served at the Company’s Executive Chairman since January 2023, has returned to his prior role as non-executive Chairman of the Board, effective April 24, 2023.

View on SEC.gov

Harmony Biosciences Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-006475

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.